GNA11 and uveal melanoma: In summary, we demonstrate that the combination of an mTOR inhibitor with a clinically relevant dosage of romidepsin is effective in cell line models of uveal melanoma that harbor pathogenic variants of GNAQ or GNA11. There is a critical need for developing a more targeted and efficacious therapy for patients with uveal melanoma and our data suggest that inhibiting the mTOR pathway in combination with romidepsin could be an effective treatment option for managing this disease.